Top 10 Stock Picks of Eli Casdin’s Casdin Capital

Published on October 31, 2022 at 8:49 am by Swati Goyal in Hedge Funds, News

In this article, we discuss the top 10 stock picks of Eli Casdin’s Casdin Capital. If you want to skip our detailed analysis of Casdin’s investment philosophy and performance, go directly to Top 5 Stock Picks of Eli Casdin’s Casdin Capital.

Unprecedented inflation, increasing interest rates, and a worldwide recession pose risks to the 10-year upward trend in the S&P 500 index in the United States (SPX). With a 16% decline this year, the S&P 500 stock index is on track to have its most challenging year since 2008. As a result, the performance of hedge funds is anticipated to be at its lowest point in ten years, indicating that stock-picking tactics may be losing favor. In the year ending July 31, the global cumulative returns of stock-buying and stock-selling funds fell 12.24%. Year-to-date results for 2022 have declined by 11.42%.

Eli Casdin’s Casdin Capital portfolio value also decreased from $2.23 billion in Q1 to $1.18 billion in Q2 2022. It is a hedge fund located in New York and was established in 2011. As of October 2020, the hedge fund was managing about $2.2 billion in assets. The fund made five new purchases in the second quarter, made additional purchases in 2 stocks, sold out of 12 equities, and reduced holdings in 19 stocks.

Source:Pixabay

Casdin Capital invests in early-stage to late-stage private enterprises and operates a long-short equity fund. In the second quarter of 2022, the hedge fund made investments primarily in the medical (76.46%) sector. It is in a good position to profit from a disruptive, undervalued technology transition that is now taking place in the life sciences and healthcare sector. Investment possibilities are available throughout the healthcare spectrum and in industries including manufacturing, agriculture, and conventional information technology. Due to its extensive engagement and experience, Casdin Capital is one of the few knowledgeable investors in the field. Some of the notable holdings in the healthcare sector include Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), McKesson Corporation (NYSE:MCK), and Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Our Methodology

We have selected the top 10 stocks from Eli Casdin’s second quarter 13F holdings. We have assessed the hedge fund sentiment from Insider Monkey’s database of 895 elite hedge funds tracked as of the end of the second quarter of 2022.

Top Stock Picks of Eli Casdin’s Casdin Capital

10. Verve Therapeutics, Inc. (NASDAQ:VERV)

Casdin Capital’s Stake Value: $47,951,000

Percentage of Casdin Capital’s 13F Portfolio: 4.05%

Number of Hedge Fund Holders: 19

Verve Therapeutics, Inc. (NASDAQ:VERV) is a genetic pharmaceuticals firm working on a novel approach for the treatment of cardiovascular disease. Eli Casdin’s Casdin Capital owned 3.14 million shares of Verve Therapeutics, Inc. (NASDAQ:VERV) in Q2 2022, worth around $47.95 million. The company has featured on Casdin’s portfolio since the second quarter of 2021.

Given his cautious outlook on VERVE-101, Credit Suisse analyst Richard Law initiated coverage of Verve Therapeutics, Inc. (NASDAQ:VERV) on October 6, assigning the stock a ‘Neutral’ rating and a $48 price target. Verve Therapeutics, Inc. (NASDAQ:VERV) developed the novel experimental gene editing medication VERVE-101 as a single-course treatment to permanently silence the PCSK9 gene in the liver and reduce disease-causing low-density lipoprotein cholesterol (LDL-C).

19 out of the 895 hedge funds tracked by Insider Monkey held stakes in Verve Therapeutics, Inc. (NASDAQ:VERV) in the second quarter of 2022, worth $200.48 million, compared to the same number of funds in the preceding quarter, holding stakes in Verve Therapeutics, Inc. (NASDAQ:VERV) valued at $272.48 million.

Just like Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), McKesson Corporation (NYSE:MCK), and Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Verve Therapeutics, Inc. (NASDAQ:VERV) is a notable stock to consider.

9. Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Casdin Capital’s Stake Value: $48,724,000

Percentage of Casdin Capital’s 13F Portfolio: 4.11%

Number of Hedge Fund Holders: 41

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a commercial stage bio-pharmaceutical company that specialises in the research and development of RNA-targeted medicines, gene therapies, and other genetic therapeutic modalities for the treatment of uncommon ailments.

As of September 8, Morgan Stanley analyst Matthew Harrison maintained an ‘Equal Weight’ rating on Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shares due to his worries over the Phase 3 EMBARK trial and his conservative estimate of the study’s 60% probability of success. However, he raised his price objective on Sarepta Therapeutics, Inc. (NASDAQ:SRPT) from $100 to $135 since he realised that the share price does not yet fully represent the option value associated with an early filing.

According to regulatory filings for the second quarter, Eli Casdin’s Casdin Capital owned 650,000 shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) worth $48.72 million, which represented 4.11% of the fund’s overall portfolio. The hedge fund reduced its stake in the firm by 19% in the second quarter of 2022.

At the end of the second quarter of 2022, 41 hedge funds in the database of Insider Monkey held stakes worth $1.38 billion in Sarepta Therapeutics, Inc. (NASDAQ:SRPT), down from 42 the preceding quarter worth $1.33 billion.

8. Fate Therapeutics, Inc. (NASDAQ:FATE)

Casdin Capital’s Stake Value: $52,038,000

Percentage of Casdin Capital’s 13F Portfolio: 4.39%

Number of Hedge Fund Holders: 23

Fate Therapeutics, Inc. (NASDAQ:FATE) is an American clinical-stage bio-pharmaceutical firm. It is working on programmed cellular immuno-therapies for cancer and immunological diseases. In the second quarter, Casdin Capital sold 1.30 million shares of Fate Therapeutics, Inc. (NASDAQ:FATE), reducing its stake by about 39%. At of the end of the quarter, the hedge fund still held more than 2.10 million shares of Fate, worth about $52.04 million. The company stands eighth on the list of top 10 stock picks of Eli Casdin’s Casdin Capital.

Canaccord analyst Bill Maughan initiated coverage of Fate Therapeutics, Inc. (NASDAQ:FATE) on October 10, assigning the stock a ‘Buy’ rating and a $42 price target. With many years of clinical development expertise and nine clinical initiatives, Fate is one of the most advanced natural killer (NK) cell firms in clinical research, according to Maughan.

Out of the hedge funds tracked by Insider Monkey, 23 hedge funds were long Fate Therapeutics, Inc. (NASDAQ:FATE) during the second quarter with aggregate stakes worth $774.28 million. This is compared to 31 hedge funds in the prior quarter which held $1.26 billion worth of positions in Fate Therapeutics, Inc. (NASDAQ:FATE).

7. SomaLogic, Inc. (NASDAQ:SLGC)

Casdin Capital’s Stake Value: $55,999,000

Percentage of Casdin Capital’s 13F Portfolio: 4.73%

Number of Hedge Fund Holders: 30

SomaLogic, Inc. (NASDAQ:SLGC), based in Boulder, Colorado, is a protein biomarker research and clinical diagnostics firm. Casdin Capital, the leading shareholder in SomaLogic, Inc. (NASDAQ:SLGC) during Q2 2022, held 12.39 million shares of the firm valued at roughly $56 million and representing 4.73% of the fund’s total holdings. With a market capitalization of $570.539 million, SomaLogic, Inc. (NASDAQ:SLGC) has generated returns of 6.55% to its shareholders over the past one month as of October 26.

On August 16, Cowen analyst Dan Brennan maintained an ‘Outperform’ rating while reducing his price objective on SomaLogic, Inc. (NASDAQ:SLGC) from $11 to $9. The analyst asserted that investors were preparing for a bad conclusion even though there has never been a decline in large pharma demand.

The number of hedge funds tracked by Insider Monkey having stakes in SomaLogic, Inc. (NASDAQ:SLGC) fell to 30 in Q2 2022 from 37 in the previous quarter. The hedge funds held stakes in the firm worth $167.51 million in Q2, down from $434.57 million in Q1.

6. Blueprint Medicines Corporation (NASDAQ:BPMC)

Casdin Capital’s Stake Value: $58,087,000

Percentage of Casdin Capital’s 13F Portfolio: 4.91%

Number of Hedge Fund Holders: 26

Blueprint Medicines Corporation (NASDAQ:BPMC) is a multinational precision therapy firm that develops treatments for cancer and blood diseases. Cadian Capital is the top shareholder of Blueprint Medicines Corporation (NASDAQ:BPMC), with a stake consisting of more than 2.02 million shares worth approximately $102.06 million.

Berenberg analyst Zhiqiang Shu initiated coverage of Blueprint Medicines Corporation (NASDAQ:BPMC) on September 14, assigning the stock a ‘Buy’ rating and a $90 price target. Shu claimed that Blueprint has a history of using its unique discovery engine to produce novel drugs.

Eli Casdin’s Casdin Capital, according to 13F filings for the second quarter, owned 1.15 million shares of Blueprint Medicines Corporation (NASDAQ:BPMC) worth $58.09 million. The hedge fund’s stake in Blueprint Medicines Corporation (NASDAQ:BPMC) decreased by 26% in the second quarter, and represented 4.91% of its overall holdings.

Out of all the hedge funds tracked by Insider Monkey, 26 were long Blueprint Medicines Corporation (NASDAQ:BPMC) in the second quarter of 2022, with aggregate stakes worth $458.34 million, as compared to 29 hedge funds with stakes worth $650.58 million in the earlier quarter.

In addition to Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), McKesson Corporation (NYSE:MCK), and Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Blueprint Medicines Corporation (NASDAQ:BPMC) is one of the stocks on the radar of elite investors.

Click to continue reading and see Top 5 Stock Picks of Eli Casdin’s Casdin Capital.

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on May 7, 2025 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

AI is eating the world—and the machines behind it are ravenous.

Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink.

Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future. But there’s one urgent question few are asking:

Where will all of that energy come from?

AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city. And it’s about to get worse.

Even Sam Altman, the founder of OpenAI, issued a stark warning:

“The future of AI depends on an energy breakthrough.”

Elon Musk was even more blunt:

“AI will run out of electricity by next year.”

As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.

And that’s where the real opportunity lies…

One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play. It’s not a chipmaker. It’s not a cloud platform. But it might be the most important AI stock in the US owns critical energy infrastructure assets positioned to feed the coming AI energy spike.

As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.

The “Toll Booth” Operator of the AI Energy Boom

It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy.
It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine.

Trump has made it clear: Europe and U.S. allies must buy American LNG.

And our company sits in the toll booth—collecting fees on every drop exported.

But that’s not all…

As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.

AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.

While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.

AI needs energy. Energy needs infrastructure.

And infrastructure needs a builder with experience, scale, and execution.

This company has its finger in every pie—and Wall Street is just starting to notice.

Wall Street is noticing this company also because it is quietly riding all of these tailwinds—without the sky-high valuation.

While most energy and utility firms are buried under mountains of debt and coughing up hefty interest payments just to appease bondholders…

This company is completely debt-free.

In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.

It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines without paying a premium.

And here’s what the smart money has started whispering…

The Hedge Fund Secret That’s Starting to Leak Out

This stock is so off-the-radar, so absurdly undervalued, that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.

They’re sharing it quietly, away from the cameras, to rooms full of ultra-wealthy clients.

Why? Because excluding cash and investments, this company is trading at less than 7 times earnings.

And that’s for a business tied to:

The AI infrastructure supercycle
The onshoring boom driven by Trump-era tariffs
A surge in U.S. LNG exports
And a unique footprint in nuclear energy—the future of clean, reliable power

You simply won’t find another AI and energy stock this cheap… with this much upside.

This isn’t a hype stock. It’s not riding on hope.

It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 100+% Return within 12 to 24 months.

We’re now offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $9.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on our AI, Tariffs, and Nuclear Energy Stock with 100+% potential upside within 12 to 24 months

• BONUS REPORT on our #1 AI-Robotics Stock with 10000% upside potential: Our in-depth report dives deep into our #1 AI/robotics stock’s groundbreaking technology and massive growth potential.

• One New Issue of Our Premium Readership Newsletter: You will also receive one new issue per month and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Content: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a month of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• Lifetime Price Guarantee: Your renewal rate will always remain the same as long as your subscription is active.

• 30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

Insider Monkey Ads

A New Dawn is Coming to U.S. Stocks

Published on January 7, 2025 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up

Top 10 Stock Picks of Eli Casdin’s Casdin Capital

Published on October 31, 2022 at 8:49 am by Swati Goyal in Hedge Funds, News

Top Stock Picks of Eli Casdin’s Casdin Capital

10. Verve Therapeutics, Inc. (NASDAQ:VERV)

9. Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

8. Fate Therapeutics, Inc. (NASDAQ:FATE)

7. SomaLogic, Inc. (NASDAQ:SLGC)

6. Blueprint Medicines Corporation (NASDAQ:BPMC)

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on May 7, 2025 at by Inan Dogan, PhD

A New Dawn is Coming to U.S. Stocks

Published on January 7, 2025 at by Insider Monkey Staff

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Premium

Log In

Sign Up

Top 10 Stock Picks of Eli Casdin’s Casdin Capital

Published on October 31, 2022 at 8:49 am by Swati Goyal in Hedge Funds, News

Share

Top Stock Picks of Eli Casdin’s Casdin Capital

10. Verve Therapeutics, Inc. (NASDAQ:VERV)

9. Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

8. Fate Therapeutics, Inc. (NASDAQ:FATE)

7. SomaLogic, Inc. (NASDAQ:SLGC)

6. Blueprint Medicines Corporation (NASDAQ:BPMC)

Share

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on May 7, 2025 at by Inan Dogan, PhD

A New Dawn is Coming to U.S. Stocks

Published on January 7, 2025 at by Insider Monkey Staff